Our MP1000 Platform
MetrioPharm is developing a new class of drugs to enable a full lifespan free of chronic and degenerative diseases.
Compounds from the MP1000 platform are orally available small molecules with a potent anti-inflammatory activity targeting the reduction of oxidative stress in immune cells.
MetrioPharm's lead drug MP1032 has demonstrated pronounced anti-inflammatory and disease-modifying activity in a number of disease models, for example, arthritis, inflammatory bowel disease, multiple sclerosis, and severe infections (sepsis).
MP1032 is currently in Phase II clinical development with psoriasis as the lead indication. Psoriasis serves as a human inflammation model for many other chronic inflammatory diseases. Our initial clinical data indicate disease-modifying activity paired with an exceptional safety and tolerability profile.